# VA Dual Sequential Therapy

> **NCT06929962** · PHASE4 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 600 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Vonoprazan and Amoxicillin for the first 7 days
- **DRUG:** Vonoprazan and Amoxicillin for the first 5 days
- **DRUG:** Vonoprazan and Amoxicillin for the second 7 days
- **DRUG:** Vonoprazan and Amoxicillin for the second 5 days
- **DRUG:** Vonoprazan and Amoxicillin for 14 days

## Key facts

- **NCT ID:** NCT06929962
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-24
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06929962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06929962, "VA Dual Sequential Therapy". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06929962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*